Ratings by Guggenheim (Brad Canino)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/31/2026 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 8/26/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 8/17/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 7/28/2026 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | AN2 Therapeutics | ANTX | New Coverage | Buy (N/A) |
4.67 (5.69) |
21.84% | Details | |
| 6/10/2026 | Nuvalent | NUVL | Downgrade | Neutral (Buy) |
123.25 (123.96) |
0.58% | Details | |
| 6/3/2026 | Celcuity Inc | CELC | Maintain | Buy (Buy) |
|
Details | ||
| 5/26/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
23.09 (23.10) |
0.04% | Details | |
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2026 | Tyra Biosciences | TYRA | New Coverage | Buy (N/A) |
35.62 (23.54) |
-33.91% | Details | |
| 3/17/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2026 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
11.92 (21.00) |
76.17% | Details | |
| 1/21/2026 | Crescent Biopharma Inc | CBIO | New Coverage | Buy (N/A) |
13.98 (19.46) |
39.2% | Details | |
| 12/8/2025 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2025 | Galecto | GLTO | New Coverage | Buy (N/A) |
17.39 (28.69) |
64.98% | Details | |
| 11/20/2025 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
61.44 (117.00) |
90.43% | Details | |
| 10/8/2025 | CG Oncology | CGON | New Coverage | Buy (N/A) |
38.13 (72.00) |
88.83% | Details | |
| 10/8/2025 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
11.06 (10.69) |
-3.35% | Details | |
| 9/22/2025 | Celcuity Inc | CELC | New Coverage | Buy (N/A) |
55.03 (85.49) |
55.35% | Details | |
| 9/4/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
10.38 (12.07) |
16.28% | Details | |
| 9/4/2025 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
23.84 (17.00) |
-28.69% | Details | |
| 9/4/2025 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
22.86 (17.68) |
-22.66% | Details | |
| 9/4/2025 | Relay Therapeutics | RLAY | New Coverage | Buy (N/A) |
3.66 (18.89) |
416.12% | Details | |
| 9/4/2025 | C4 Therapeutics | CCCC | New Coverage | Buy (N/A) |
2.51 (3.40) |
35.46% | Details |
